
    
      This is a double-blind, placebo-controlled, randomized, parallel group study. Three different
      doses of APD356 or placebo will be administered daily for 28 days, to uncomplicated obese,
      male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400
      subjects will be enrolled.
    
  